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1 Introduction
Metronidazole has become a commonly used
antimicrobial agent in the treatment of puerperal
infections. It is, however, generally recommended
that women do not breast-feed during metro-
nidazole therapy [1, 3, 8, 15] as a number of
studies have demonstrated metronidazole in
breast milk in concentrations which do not differ
markedly from corresponding maternal blood
levels [2, 7, 9, 14]. It has been stated [8] that
isolated measurements of a drug in breast milk is
of little significance and that both the mother and
infant must be examined as drug absorption in the
neonate may be limited or facilitated compared to
the adult. Also, excretion and metabolism may
be decreased in the neonate organism causing
accumulation of the drug.
To our knowledge no studies have measured
comparative levels of metronidazole in mothers
and infants during therapeutic administration for
puerperal infection in lactating mothers. We have
performed such a study measuring the levels of
metronidazole and its hydroxy metablite (I) in
milk and blood of mothers and their suckling
infants with a specific method. The object was to
assess the amounts of the drug and its hydroxy-
metabolite in the infant organism and their rates
of clearance. We also analysed a series of simulta-
neous milk and blood samples in one mother and
calculated milk/plasma and infant/mother plasma
ratios.
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2 Material and method
Fifteen mothers in treatment for puerperal endo-
metritis with metronidazole tablets consented
to participate. Four of the patients received
400 mg and eleven 200 nig three times daily.
All women received additional therapy, thirteen
with pivampicillin tablets 350mg and two with
erythromycin tablets 500mg three times daily.
The medication was started from 0 to 22 days
after parturition and all samples collected from at
least 1 day after treatment start and up to 9 days
after treatment start.
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Maternal blood samples were collected from two
hours after intake of a tablet until next breast-feed
irrespective of medication when a simultaneous
blood and milk sample were taken. One mother
had a series of synchronous blood and milk
samples collected, i.e. at 10,30, 60, 120, 180, and
240 minutes after medication.
At the time of milk sampling the infants were
test weighed and 1 to 2 hours later they had a
blood sample taken as peak plasma concentrations
occur within 30 minutes to 3 hours after oral
administration [4].
The analyses for metronidazole and its hydroxy
metabolite (I) in milk and plasma were performed
as a specific semi-micro high-pressure liquid
Chromatographie method as described by K.AYE
and co-workers [10]. The limit of sensitivity was
less than 0.1
3 Results
Concentrations of metronidazole and its hydroxy
metabolite (I) in milk and in infant and maternal
plasma are shown in Tabs. I and II. Mean and
range for maternal and infant plasma levels and
milk levels as well as milk/plasma ratios in mothers
and infant/mother plasma ratios are shown in
Tabs. Ill and IV for metronidazole and hydroxy
metabolite (I).
Simultaneous milk and blood samples in one
woman show almost identical levels of metro-
nidazole and hydroxy metabolite (I) from 10 to
240 minutes after dosing (Tab. V).
Judging from milk levels the maximum dose of
metronidazole ingested by one infant in one meal
was 1.8mg/100mg and assuming a total daily
intake of 500 ml and an average neonatal weight
of 3.0 kg the amount taken would be 3.0 mg/kg/
day.
The ratio between maternal and infant total
clearance can be calculated, as Clm = Dm χ F/Cm,
where Clm is total maternal clearance, Dm mater-
nal dosage, F absorption fraction and Cm mean
maternal plasma concentration and as Clj = D, x
F/Cj = V χ Cm χ Μ/Ρ χ F/Cj where Clj is total
infant clearance, Dj infant dosage, Q mean infant
plasma concentration, V milk volume ingested
daily and M/P milk/plasma ratio which we equal 1
(Tab. III). The ratio is then Clj/Clm = V χ C^/
(CjxDm). With V = 500ml the ratio is then
0.026 for Dm=600mg, Cm = 5.0Mg/ml and
Cj = 0.8Mg/ml and 0.027 for Dm = 1200mg,
Tab. I. Concentrations of metronidazole (M.) in Mg/ml in mothers and infants. Time after dosing/feed in minutes.
Infant
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
mg/uay
600
600
1200
600
600
600
(twins)
600
600
600
600
600
1200
600
1200
1200
Plasma
Time
120
140
120
120
130
120
120
120
120
120
105
140
140
120
See Tab.
Cone.
8.8
3.3
7.8
1.9
6.6
4.5
8.3
1.0
3.4
4.2
5.0
3.7
4.3
13.5
V
Time
270
120
240
0
240
240
240
240
30
240 -
240
135
20
180
Cone.
7.8
1.7
8.5
4.6
5.0
3.5
7.9
1.0
5.6
4.2
3.9
13.6
5.3
11.7
Time
120
30
120
120
150
180
60
240
Cone.
15.5
5.2
5.7
11.6
3.8
5.5
6.1
9.6
Milk
Time
270
120
120
30
240
120
120
150
30
180
60
135
20
180
Cone.
6.2
1.6
12.9
5.3
5.0
5.5
12.2
4.4
7.0
5.8
3.8
13.1
5.8
11.6
Plasma
Time
120
*)
45
60
120| 60
\ 60
60
60
60
60
60
60
60
120
Cone.
1.4
—
4.9
0.3
0.6
0.6
0.5
0.6
0.7
1.1
1.0
0.4
0.6
1.2
2.3
Sample too small to analyse
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Cm = 12.5 A/g/ml, and Q = 2.4 Mg/ml. If we assume
infant and maternal weights to be 3.0 and 70.0 kg
and body surfaces to be 0.2 m2 and 1.8 m2 infant
clearance is 61% and 63% of maternal clearance
by weight and 23 % and 24 % by body surface.
No adverse reactions were observed in mothers or
infants.
4 Discussion
Breast-feeding involves benefits for the infant and
its mother. Administration of drugs to the mother
during the lactating period always raises the
question of the possible harmful effects of the
drug to the infant as virtually all drugs via the milk
Tab. II. Concentrations of hydroxy metabolite I in Mg/ml in mothers and infants. Time after dosing/feed in minutes.
Patient M.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
mg/uay
600
600
1200
600
600
600
(twins)
600
600
600
600
600
1200
600
1200
1200
Mother
Plasma
Time
120
140
120
120
130
120
120
120
120
120
105
140
140
120
See Tab.
Cone.
3.4
1.7
1.7
1.2
1.2
1.8
2.6
0.9
1.1
1.5
1.0
3.9
1.2
4.9
V
Time
270
120
240
0
240
240
240
240
30
240
240
135
20
180
Cone.
4.0
1.7
1.8
1.2
1.2
1.9
2.8
0.8
1.4
1.7
1.3
5.4
1.2
5.3
Time
120
30
120
120
150
180
60
240
Cone.
2.4
1.5
1.9
3.1
0.9
1.9
1.6
1 ,
' -5.5
Milk
Time
270
120
120
30
240
120
120
150
30
180
60
135
20
180
Cone.
3.0
1.9
2.8
2.0
1.4
2.4
3.8
1.3
1.9
2.1
1.1
5.9
1.7
6.3
Infant
Plasma
Time
120
*)
45
60
120
/ 60
\ 60
60
60
60
60
60
60
60
120
Cone.
0.8
—
2.3
0.2
n.d.
0.5
0.5
0.4 ·
0.2
0.5
0.6
0.2
0.7
0.6
1.1
*) Sample too small to analyse,
n.d.: Not detectable, i.e. less than 0.1 Mg/ml.
Tab. III. Concentrations of metronidazole in breast milk and infant and maternal plasma in Mg/ml and milk/plasma and
infant/mother plasma ratios.
Metronidazole
mg/day
600
1200
Metronidazole
mg/day
600
1200
Number
patients
11
4
Number
patients
11
4
Concentrations of metronidazole in
mothers
plasma
mean range
5.0 1.0-11.6
12.5 3.7-17.9
mothers milk/plasma
mean
Oa.99
0.98
range
0.62-1.25
0.83-1.13
milk
mean range
5.7 1.6-12.2
14.4 11.6-18.0
baby /mother plasma
mean
0.13
0.17
range
0.05-0.23
0.04-0.32
infants
plasma
mean range
0.8 0.3-1.4
2,4 . 0.6-4.9
(
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Tab. IV. Concentration of hydroxy metabolite (I) in breast milk and infant and maternal plasma in Mg/ml and milk/
plasma and infant/mother plasma rations.
Metronidazole
mg/day
600
1200
Metronidazole
mg/day
600
1200
Number
patients
11
4
Number
patients
11
4
Concentrations of hydroxy
mothers
plasma
mean
1.7
3.2
mothers
mean
1.17
1.20
range
0.8-4.0
1.7-5.5
milk/plasma
range
0.69-1.44
1.04-1.35
metabolite
milk
mean range
2.1 1.1-3.8
3.5 2.4-6.3
baby /mother plasma
mean
0.23
0.37
range
0.08-0.50
0.13-0.96
infants
plasma
mean range
0.4 0.1-0.8
1.1 0.4-2.3
reach the infant organism. The safety evaluation of
metronidazole is based mainly on animal studies
and clinical experience derived from the adult
population [5, 13]. Absorption of metronidazole
in neonates may be altered and as metronidazole
is primarily excreted by the kidneys, the newborn
may accumulate the drug resulting in higher
concentrations than in the adult organism. Studies
[2, 7, 9, 14] dealing with metronidazole adminis-
tration to lactating women involve only few
infants and only one study besides the present has
analysed infant blood levels.
GRAY and co-workers' [9] study involved 10
mothers who were given a single tablet of 200 mg
metronidazole. Mean concentrations in breast milk
varied between 1.3 and 3.4 Mg/ml and between 1.8
and 3.9 Mg/ml in serum. Blood tests from 5 babies
contained no detectable metronidazole and in 5,
levels ranged from 0.05 to 0.4 g/ml. The maxi-
mum amount ingested by one infant calculated
from test weighings was 0.41 mg. As expected
these figures all range below our findings which
are based on the therapeutic administration of
metronidazole to the mothers.
AMON et aL [2] examined 6 puerperae who were
given 250 mg metronidazole orally twice daily.
The highest level in breast milk was found to be
6.8Mg/ml and the maximum amount actually
taken by the newborn was 0.17 mg/kg/100 ml
milk which is about one third of the amount we
have estimated. The coefficient of distribution
milk: Serum was below 1.0 in four and above 1.0
in two mothers which compares well with our
milk/plasma ratios.
The administration of metronidazole in the Study
Group [14] report is the only one comparable to a
Tab. V. Simultaneous maternal milk, and plasma concentrations in Mg/ml of metronidazole and hydroxy metabolite (I)
in one mother receiving 1200 mg metronidazole daily.
Time in minutes after medication
Metronidazole
Hydroxy met.
Plasma
Milk
Plasma
Milk
10
11.7
13.2
1.9
2.5
30
12.2
13.4
2.0
2.7
60
15.4
13.2
2.2
2.4
120
17.8
18.0
2.3
3.0
180
17.9
17.6
2.5
2.6
240
16.3
16.3
2.4
3.0
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clinical administration of the drug, i.e. 200 mg
oral metronidazole at eight-hourly intervals. Milk
samples from mothers contained a mean of 4.7
(range 1.1-15.2) Mg/ml and blood a mean of 7.8
(range 2.0-14.6) Mg/ml. These findings are in
accordance with the ones in the present study,
where the range too is almost 10-fold. The varia-
tion in our study was seen between mothers as
samples from the same mother showed less varia-
tions (Tab. I). This inter-maternal variation is
probably due to differences in body weight and
intestinal absorption.
ERICKSON etal. [7] measured metronidazole
concentrations in breast milk from 3 women
who had been treated with a single 2 gram dose.
Estimated consumption based on I3000mg breast
milk intake by a baby was 21.8mg during the
first 24 hours.
No pharmacokinetic studies of metronidazole have
involved neonates why the intestinal absorption is
unknown. Assuming that the mean maternal and
infant plasma levels represent steady state concen-
trations we calculated the infant total clearance to
be around 60% by weight and around 24% by
body surface of the maternal clearance. This
finding is in good accordance with the clearance
ratios found for other antimicrobial chemothera-
peutics such as gentamycin [12]. The fraction is
apparently independent of the daily intake. The
maximum intake by an infant in our study was
calulated to be 3.0mg/kg with 500ml milk
intake per day which is well below the advocated
10—20mg/kg metronidazole dosage in the treat-
ment of infants. On the other hand, a 1200 rng
daily intake of metronidazole by the mother may
result in almost therapeutic levels.in infants.
The hydroxy metabolite (I) like the parent com-
pound is known to possess antimicrobial and
mutagenic activity. The antimicrobial activity
of the metabolite tested on clostridial species
was found to be 30% of metronidazole [6] where-
as the mutagenic activity tested in vitro with
Salmonella Typhimurium was found to be 10
times higher [11]. The significance of these find-
ings in humans is unknown. In all instances we
found the levels of the hydroxy metabolite (I)
to be considerably lower than those of metro-
nidazole.
Our conclusion is that infants do receive metro-
nidazole via breast milk in considerable doses and
attain measurable levels in their organisms. On
these grounds, it seems wise to prescribe metro-
nidazole with caution to lactating women. The
ultimate decision whether to stop or continue
breastfeeding
 ( during metronidazole therapy still
has to be based on our insufficient knowledge of
the possible long-term harmful effects of the drug
on the neonate, as only few and mild instant
adverse reactions are seen.
Summary
In order to assess the amounts of metronidazole and
its clearance in suckling neonates whose mothers received
the drug in therapeutic doses, we measured its levels in
maternal plasma and milk and in infant plasma. Eleven
mothers receiving 600 mg metronidazole daily and 4
receiving 1200mg and their 15 infants had milk and
plasma levels determined with a specific semi-micro
high-pressure liquid Chromatographie method. Maternal
mean plasma levels were 5.0 Mg/ml, range 1.0-11.6 Mg/ml
(600mg/day) and 12.5 Mg/ml range 3.7-17.9 Mg/ml
(1200mg/day) and corresponding infant plasma levels
were 0.8 Mg/ml, range 0.3-1.4 Mg/ml and 2.4 Mg/ml,
range 0.6-4.9 Mg/ml. Maternal milk/plasma ratio was 1
and baby/mother plasma ratio was 0.15, independent of
dosage (Tab. I). The levels of metronidazole hydroxy
metabolite (I) were all below those of metronidazole
(Tab. II). Simultaneous milk and blood samples showed
almost identical levels (Tab. III).
Infant total clearance of metronidazole was calculated to
be ca. 60 % of maternal clearance by body weight and
24% by body surface, independent of dosage, while
maximum infant metronidazole intake was estimated to
be 3.0mg/kg/day assuming a daily intake of 500ml
milk. It is recommended to avoid simultaneous breast-
feeding and metronidazole therapy until possible harmful
longterm effects on the neonates are known.
Keywords: Infant clearance, infant plasma levels, lactation, metronidazole.
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Zusammenfassung
Metronidazolplasmaspiegel bei Müttern und ihren Neu-
geborenen und Konzentration in der Brustmilch
Ziel unserer Untersuchung war die Ermittlung der
Metronidazol-Konzentration bzw. -Clearance bei gestillten
Neugeborenen, deren Mütter mit diesem Medikament in
therapeutischen Dosen behandelt wurden. Dazu bestimm-
ten wir die Plasmaspiegel bei Mutter und Kind sowie
die Konzentration in der Brustmilch. 11 Mütter erhielten
600mg Metronidazol pro Tag und 4 Mütter 1200mg
pro Tag. Die Konzentrationen wurden mit einer spezifi-
schen Methode, der Hochdruckflüssigkeitschromatogra-
phie, ermittelt. Bei den Frauen, die 600 mg/d erhielten,
lagen die Plasmaspiegel zwischen 1.0 und 11.6 /ig/ml, also
durchschnittlich 5.0 Mg/ml; Mütter, die 1200 mg/d erhiel-
ten, wiesen Plasmaspiegel zwischen 3.7 und 17.9 Mg/ml,
d.h. durchschnittlich 12.5 Mg/ml auf. Bei den Neuge-
borenen wurden bei der geringeren Tagesdosis mittlere
Spiegel von 0.8 Mg/ml (0.3-1.4 Mg/ml) bestimmt, bei der
doppelten Dosis lag er bei durchschnittlich 2.4 Mg/ml
(0.6-4.9 Mg/ml). Das Verhältnis zwischen mütterlichem
Plasmaspiegel und Brustmilch betrug l, das Verhältnis
von kindlichem zu mütterlichem Plasmaspiegel lag
unabhängig von der Dosis bei 0.15 (Tab. I). Die Konzen-
tration der Metaboliten lag in jedem Fall unter der von
Metronidazol (Tab. H). Die gleichzeitige Bestimmung in
Milch- und Plasmaproben ergab fast immer identische
Spiegel (Tab. III). Die totale Metronidazol-Clearance beim
Kind berechnete sich zu 60 % der mütterlichen Clearance
durch das Körpergewicht und zu 24 % durch die Körper-
oberfläche. Sie zeigte sich unabhängig von der Dosierung.
Die maximale Metronidazolaufnahme durch das Kind
wurde auf 3.0 mg/kg/d geschätzt, wenn man eine tägliche
Trinkmenge von 500 ml Milch ansetzt. Wir empfehlen,
unter Metronidazoltherapie mit dem Stillen aufzuhören,
da schädigende Wirkungen auf das Neugeborene nicht
ausgeschlossen werden können.
Schlüsselwörter: Clearance beim Kind, Laktation, Metronidazol, Plasmaspiegel beim Kind.
Resume
Concentration de metronidazole dans le sang et dans le
lait chez les meres et les enfants
Les auteurs ont mesure les taux de metronidazole dans le
plasma maternel et le lait ainsi que dans le plasma des
enfants, afin de determiner les quantites de metronidazole
et sä clearance chez les nouveaux-nes nourris au sein dont
les meres re$oivent ce produit a doses therapeutiques. Les
taux plasmatiques et du lait ont ete mesures ä l'aide d'une
semi-micro methode specifique par Chromatographie avec
liquide ä haute pression, chez 11 meres recevant 600 mg
de metronidazole par jour et chez 4 recevant 1200 mg de
metronidazole par jour ainsi que chez leurs 15 enfants.
La moyenne des taux plasmatiques maternels est de
5 Mg/ml, avec des ecarts compris entre l et 11,6 Mg/ml
(600 mg/ jour) et 12,5 Mg/ml avec des ecarts allant de 3,7
a 17,9 Mg/ml (1200 mg/jour), tandis que les taux plasma-
tiques correspondants des enfants sont de 0,8 Mg/ml, avec
des ecarts de 0,3 ä 1,4 Mg/ml et 2,4 Mg/ml, avec des ecarts
de 0,6 ä 4,9 Mg/ml. Le rapport lait maternel/plasma est de
I et le rapport plasmatique enfant/mere est de 0,15,
independamment des dosages (Tab. I). Les taux de
metabolite hydroxyle du metronidazole (I) sont tous
en-dessous de ceux du metronidazole (Tab. II). Les
echantillons simultanes de lait et de sang montrent des
taux ä peu pres identiques (Tab. III).
La clearance totale du metronidazole chez l'enfant a ete
determinee ä 60 % de la clearance maternelle en fonction
du poids corporel, et ä 24 % en fonction de la surface
corporelle sans lien avec la posologie, alors que Tapport
maximum de metronidazole chez l'enfant a ete estime
ä 3 mg/Kg/jour, ce qui correspond ä une quantite jour-
naliere de 500 ml de lait.
II est recommande d'eviter l'allaitement au sein lors des
traitements par metronidazole, tant qu'un eventuel effet
nocif ä long terme chez le nouveau-ne n'aura pas ete
elimine.
Mots-cles: Allaitement, clearance chez l'enfant, metronidazole, taux plasmatique de l'enfant.
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